NewAmsterdam Pharma Past Earnings Performance
Past criteria checks 0/6
NewAmsterdam Pharma's earnings have been declining at an average annual rate of -82.5%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been declining at an average rate of 32.3% per year.
Key information
-82.5%
Earnings growth rate
-28.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -32.3% |
| Return on equity | -59.2% |
| Net Margin | -3,090.0% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How NewAmsterdam Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 7 | -229 | 51 | 165 |
| 31 Mar 24 | 7 | -229 | 44 | 161 |
| 31 Dec 23 | 14 | -177 | 38 | 159 |
| 30 Sep 23 | 18 | -167 | 35 | 144 |
| 30 Jun 23 | 11 | -162 | 27 | 128 |
| 31 Mar 23 | 61 | -94 | 23 | 111 |
| 31 Dec 22 | 103 | -23 | 20 | 87 |
| 30 Sep 22 | 97 | -8 | 17 | 71 |
| 30 Jun 22 | 98 | 37 | 13 | 49 |
| 31 Mar 22 | 52 | 4 | 10 | 40 |
| 31 Dec 21 | 0 | -42 | 6 | 29 |
Quality Earnings: NAMS is currently unprofitable.
Growing Profit Margin: NAMS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NAMS is unprofitable, and losses have increased over the past 5 years at a rate of 82.5% per year.
Accelerating Growth: Unable to compare NAMS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NAMS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: NAMS has a negative Return on Equity (-59.21%), as it is currently unprofitable.